These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
311 related articles for article (PubMed ID: 31161586)
1. Valuation of EQ-5D-5L Health States in Poland: the First EQ-VT-Based Study in Central and Eastern Europe. Golicki D; Jakubczyk M; Graczyk K; Niewada M Pharmacoeconomics; 2019 Sep; 37(9):1165-1176. PubMed ID: 31161586 [TBL] [Abstract][Full Text] [Related]
2. A hybrid modelling approach for eliciting health state preferences: the Portuguese EQ-5D-5L value set. Ferreira PL; Antunes P; Ferreira LN; Pereira LN; Ramos-Goñi JM Qual Life Res; 2019 Dec; 28(12):3163-3175. PubMed ID: 31201730 [TBL] [Abstract][Full Text] [Related]
3. EQ-5D-5L: a value set for Romania. Olariu E; Mohammed W; Oluboyede Y; Caplescu R; Niculescu-Aron IG; Paveliu MS; Vale L Eur J Health Econ; 2023 Apr; 24(3):399-412. PubMed ID: 35688994 [TBL] [Abstract][Full Text] [Related]
4. Utility Values for Health States in Ireland: A Value Set for the EQ-5D-5L. Hobbins A; Barry L; Kelleher D; Shah K; Devlin N; Goni JMR; O'Neill C Pharmacoeconomics; 2018 Nov; 36(11):1345-1353. PubMed ID: 30051267 [TBL] [Abstract][Full Text] [Related]
5. Estimating an EQ-5D-Y-3L Value Set for Indonesia by Mapping the DCE onto TTO Values. Fitriana TS; Roudijk B; Purba FD; Busschbach JJV; Stolk E Pharmacoeconomics; 2022 Dec; 40(Suppl 2):157-167. PubMed ID: 36348155 [TBL] [Abstract][Full Text] [Related]
6. Valuing health-related quality of life: An EQ-5D-5L value set for England. Devlin NJ; Shah KK; Feng Y; Mulhern B; van Hout B Health Econ; 2018 Jan; 27(1):7-22. PubMed ID: 28833869 [TBL] [Abstract][Full Text] [Related]
7. Valuation of the EQ-5D-5L with composite time trade-off for the German population - an exploratory study. Ludwig K; von der Schulenburg JG; Greiner W Health Qual Life Outcomes; 2017 Feb; 15(1):39. PubMed ID: 28219389 [TBL] [Abstract][Full Text] [Related]
8. Parallel Valuation of the EQ-5D-3L and EQ-5D-5L by Time Trade-Off in Hungary. Rencz F; Brodszky V; Gulácsi L; Golicki D; Ruzsa G; Pickard AS; Law EH; Péntek M Value Health; 2020 Sep; 23(9):1235-1245. PubMed ID: 32940242 [TBL] [Abstract][Full Text] [Related]
9. Experience-Based Swedish TTO and VAS Value Sets for EQ-5D-5L Health States. Burström K; Teni FS; Gerdtham UG; Leidl R; Helgesson G; Rolfson O; Henriksson M Pharmacoeconomics; 2020 Aug; 38(8):839-856. PubMed ID: 32307663 [TBL] [Abstract][Full Text] [Related]
10. Parallel Valuation: A Direct Comparison of EQ-5D-3L and EQ-5D-5L Societal Value Sets. Law EH; Pickard AS; Xie F; Walton SM; Lee TA; Schwartz A Med Decis Making; 2018 Nov; 38(8):968-982. PubMed ID: 30403577 [TBL] [Abstract][Full Text] [Related]
11. EQ-5D-5L Value Set for Slovenia. Prevolnik Rupel V; Ogorevc M Pharmacoeconomics; 2023 Nov; 41(11):1515-1524. PubMed ID: 37341959 [TBL] [Abstract][Full Text] [Related]
12. The EQ-5D-5L Valuation Study in Egypt. Al Shabasy S; Abbassi M; Finch A; Roudijk B; Baines D; Farid S Pharmacoeconomics; 2022 Apr; 40(4):433-447. PubMed ID: 34786590 [TBL] [Abstract][Full Text] [Related]
13. United States Valuation of EQ-5D-5L Health States Using an International Protocol. Pickard AS; Law EH; Jiang R; Pullenayegum E; Shaw JW; Xie F; Oppe M; Boye KS; Chapman RH; Gong CL; Balch A; Busschbach JJV Value Health; 2019 Aug; 22(8):931-941. PubMed ID: 31426935 [TBL] [Abstract][Full Text] [Related]
14. The EQ-5D-5L valuation study for Trinidad and Tobago. Bailey H; Jonker MF; Pullenayegum E; Rencz F; Roudijk B Health Qual Life Outcomes; 2024 Jul; 22(1):51. PubMed ID: 38956543 [TBL] [Abstract][Full Text] [Related]
15. The EQ-5D-5L Valuation study in Thailand. Pattanaphesaj J; Thavorncharoensap M; Ramos-Goñi JM; Tongsiri S; Ingsrisawang L; Teerawattananon Y Expert Rev Pharmacoecon Outcomes Res; 2018 Oct; 18(5):551-558. PubMed ID: 29958008 [TBL] [Abstract][Full Text] [Related]
16. Preparatory study for the revaluation of the EQ-5D tariff: methodology report. Mulhern B; Bansback N; Brazier J; Buckingham K; Cairns J; Devlin N; Dolan P; Hole AR; Kavetsos G; Longworth L; Rowen D; Tsuchiya A Health Technol Assess; 2014 Feb; 18(12):vii-xxvi, 1-191. PubMed ID: 24568945 [TBL] [Abstract][Full Text] [Related]
17. German Value Set for the EQ-5D-5L. Ludwig K; Graf von der Schulenburg JM; Greiner W Pharmacoeconomics; 2018 Jun; 36(6):663-674. PubMed ID: 29460066 [TBL] [Abstract][Full Text] [Related]
18. Interim EQ-5D-5L Value Set for Poland: First Crosswalk Value Set in Central and Eastern Europe. Golicki D; Niewada M; Hout BV; Janssen MF; Pickard AS Value Health Reg Issues; 2014 Sep; 4():19-23. PubMed ID: 29702801 [TBL] [Abstract][Full Text] [Related]
20. Developing the EQ-5D-5L Value Set for Uganda Using the 'Lite' Protocol. Yang F; Katumba KR; Roudijk B; Yang Z; Revill P; Griffin S; Ochanda PN; Lamorde M; Greco G; Seeley J; Sculpher M Pharmacoeconomics; 2022 Mar; 40(3):309-321. PubMed ID: 34841471 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]